Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk

J Diabetes Complications. 2023 May;37(5):108468. doi: 10.1016/j.jdiacomp.2023.108468. Epub 2023 Mar 22.

Abstract

Purpose: The study compared the incidence of cancer between patients with diabetes with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors use.

Methods: This study identified a non-SGLT2 inhibitor cohort of 325,989 patients and a SGLT2 inhibitor cohort of 325,990 patients. The primary interest of this study was the occurrence of cancer. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models.

Results: Patients receiving SGLT2 inhibitors (adjusted HR = 0.79, 95 % CI = 0.76-0.83) had a significantly lower risk of developing cancer than patients without receiving SGLT2 inhibitors.

Conclusion: The results demonstrated that patients with diabetes receiving SGLT2 inhibitors had a significantly lower risk of cancer.

Keywords: Cancer; Diabetes mellitus; Sodium-glucose cotransporter-2 inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / epidemiology
  • Glucose
  • Humans
  • Neoplasms* / chemically induced
  • Neoplasms* / epidemiology
  • Risk
  • Sodium
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Glucose
  • Sodium